No connection

Search Results

ASMB vs PRTC

ASMB
Assembly Biosciences, Inc.
NEUTRAL
Price
$28.11
Market Cap
$444.7M
Sector
Healthcare
AI Confidence
72%
PRTC
PureTech Health plc
NEUTRAL
Price
$18.30
Market Cap
$445.5M
Sector
Healthcare
AI Confidence
75%

Valuation

P/E Ratio
ASMB
--
PRTC
10.7
Forward P/E
ASMB
-8.03
PRTC
-36.6
P/B Ratio
ASMB
2.43
PRTC
1.17
P/S Ratio
ASMB
11.96
PRTC
69.7
EV/EBITDA
ASMB
-4.96
PRTC
-36.48

Profitability

Gross Margin
ASMB
-66.29%
PRTC
0.0%
Operating Margin
ASMB
-100.87%
PRTC
-2589.52%
Profit Margin
ASMB
-103.65%
PRTC
792.96%
ROE
ASMB
-36.94%
PRTC
9.44%
ROA
ASMB
-15.96%
PRTC
-12.95%

Growth

Revenue Growth
ASMB
57.6%
PRTC
542.7%
Earnings Growth
ASMB
--
PRTC
--

Financial Health

Debt/Equity
ASMB
0.02
PRTC
0.44
Current Ratio
ASMB
4.44
PRTC
8.49
Quick Ratio
ASMB
4.39
PRTC
8.35

Dividends

Dividend Yield
ASMB
--
PRTC
--
Payout Ratio
ASMB
0.0%
PRTC
0.0%

AI Verdict

ASMB NEUTRAL

ASMB's Advanced Deterministic Scorecard reveals severe financial health concerns: a Piotroski F-Score of 0/9 indicates extreme operational weakness, and the absence of an Altman Z-Score raises distress risk concerns. Despite this, the company exhibits strong revenue growth (57.6% YoY) and improving earnings surprises in recent quarters, suggesting potential operational turnaround. However, negative profitability metrics—such as a -103.65% profit margin and negative ROE—highlight persistent losses. The stock trades at a premium valuation (Price/Sales of 11.96) with no dividend, reflecting high growth expectations rather than intrinsic value. Analysts maintain a target price of $47.75, implying upside, but consensus is weak with only four analysts.

Strengths
Strong revenue growth of 57.6% YoY, indicating market traction
Improving earnings surprise trend in the last four quarters (average +12.52%)
Significant recent EPS improvement: +52.3% YoY and +45.9% Q/Q
Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
Negative profitability across all margins and ROE/ROA, indicating unsustainable losses
No Graham Number or intrinsic value estimate, reflecting lack of stable earnings
PRTC NEUTRAL

PRTC presents a contradictory financial profile with a stable Piotroski F-Score of 5/9 and a strong liquidity position (Current Ratio 8.49), yet suffers from severe operational inefficiency. While the Graham Number of $24.47 suggests defensive value, the growth-based intrinsic value of $11.90 and a negative forward P/E indicate significant future earnings risk. The massive discrepancy between the reported profit margin (792.96%) and operating margin (-2589.52%) suggests the company is relying on non-operating gains rather than core business profitability. Short-term price momentum is positive, but long-term performance remains deeply depressed.

Strengths
Exceptional short-term liquidity with a Current Ratio of 8.49
Low leverage with a Debt/Equity ratio of 0.44
Explosive year-over-year revenue growth of 542.70%
Risks
Catastrophic operating margins (-2589.52%) indicating high cash burn
Negative forward P/E suggests expected losses in the coming year
Extremely high Price-to-Sales ratio (69.70) indicating overvaluation relative to revenue

Compare Another Pair

ASMB vs PRTC: Head-to-Head Comparison

This page compares Assembly Biosciences, Inc. (ASMB) and PureTech Health plc (PRTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile